Clinical Trials Logo

Carcinoma, Non-Small-Cell Lung clinical trials

View clinical trials related to Carcinoma, Non-Small-Cell Lung.

Filter by:

NCT ID: NCT01720901 Suspended - Clinical trials for Non-small Cell Lung Cancer

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Start date: February 2013
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of increased dose of icotinib in advanced NSCLC patients who progressed after gefitinib therapy.

NCT ID: NCT01356303 Suspended - Clinical trials for Non-small Cell Lung Cancer Metastatic

Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer

TAXIS01
Start date: March 2009
Phase: Phase 2
Study type: Interventional

This is a phase II, open-label clinical study prospectively enrolling 40 metastatic patients with non small cell lung cancer. The study will enroll patients at King Abdulaziz Medical City, Riyadh. Sub-sites will be open for patient accrual in selected centers in the Kingdom.

NCT ID: NCT01320501 Suspended - Clinical trials for Non-small Cell Lung Cancer Metastatic

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

REALME
Start date: October 2009
Phase: Phase 4
Study type: Interventional

An open-label, prospective, single-arm, multi-center phase IV clinical trial of TarcevaTM as single agent

NCT ID: NCT01088620 Suspended - Clinical trials for Carcinoma, Non-Small-Cell Lung

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to estimate the therapeutic efficacy of the experimental targeted regimen including the EGFR antibody panitumumab (in combination with pemetrexed and cisplatin) in relation to the standard combination in patients with a KRAS wild-type stage IIIB or IV primary nonsquamous non-small cell lung cancer. It is expected that the progression free survival rate at 6 months is improved by the targeted regimen.

NCT ID: NCT00986284 Suspended - Clinical trials for Non Small Cell Lung Cancer

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Start date: September 2009
Phase: Phase 2
Study type: Interventional

This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.

NCT ID: NCT00540280 Suspended - Clinical trials for Carcinoma, Non-Small-Cell Lung

Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer

Start date: October 2003
Phase: Phase 3
Study type: Interventional

Randomized Phase III trial of surgery alone or surgery plus preoperative Gemcitabine-Cisplatin in clinical early stages of non-small cell lung cancer

NCT ID: NCT00264472 Suspended - Neoplasms Clinical Trials

A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors

Start date: January 2006
Phase: Phase 1
Study type: Interventional

5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5 FU in subjects with refractory solid tumors.

NCT ID: NCT00211952 Suspended - Clinical trials for Non-Small Cell Lung Cancer

Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients

Start date: March 2004
Phase: Phase 3
Study type: Interventional

The aim of the study is to assess the influence of celecoxib on relapse-free survival in completely resected patients with poor prognosis indicated by metastatic involvement of intrapulmonary/hilar (pN1) or ipsilateral mediastinal (pN2) lymph nodes. Celecoxib, a selective oral COX-2 inhibitor, was found to exert significant anti-proliferative activity against a variety of tumor cell lines in vitro, including NSCLC. COX-2 is frequently up-regulated in NSCLC cell lines and archival tumor samples. Its high expression was also correlated with poor prognosis of the patients. A clinical trial addressing the role of celecoxib as adjuvant treatment in radically operated patients with high risk of relapse is warranted.